NYSE: OGN

Organon & Co.

Healthcare | Drug Manufacturers - General

No licensed closing price on file for OGN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.94

Organon & Co. (NYSE: OGN) is a drug manufacturer. Figures from SEC EDGAR; updated 2026-10-20 13:41 UTC.

What Organon & Co. does

Organon is a global healthcare company that sells prescription medicines across women's health and general medicines in over 140 countries and territories. The women's health portfolio includes contraceptive products like Nexplanon and NuvaRing, as well as fertility treatments like Follistim AQ. The general medicines portfolio comprises biosimilars targeting immunology and oncology conditions, along with established branded medicines in cardiovascular, respiratory, dermatology and pain management.

Summarized from Organon & Co.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-11
EPS (TTM)	$0.94
Return on equity	24.87%
Debt/equity	9.51

Revenue Trend

Annual Revenue · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-12

2026-08-12Head of R&D & CMOTax withholding-4,134$56.3K
2026-08-12Head of R&D & CMORestricted Stock UnitsOption exercise11,519—
2026-08-12Head of R&D & CMOOption exercise11,519—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

BlackRock, Inc.32,056,866$434.05M+44.3%
Pentwater Capital Management LP18,100,000$245.07MNEW
VANGUARD PORTFOLIO MANAGEMENT LLC15,132,118$204.89M-30.7%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-10-27Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2021-06-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersShalini SharpAuthoritativeSEC 8-K →

Company news

View all →

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com2026-07-15
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
zacks.com2026-06-22
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Organon & Co. do?

Organon is a global healthcare company that sells prescription medicines across women's health and general medicines in over 140 countries and territories.

When did OGN last file with the SEC?

Organon & Co.'s most recent SEC filing on record is a 8-K filed 2026-06-11. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:41 UTC. This page is also available as JSON at /api/data?ticker=OGN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for OGN and 5,000+ tickers.

Create a free account — keep OGN

For your agent

GET /api/data?ticker=OGN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt